PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction. PF-06952229 is a promising antineoplastic agent for the study solid tumors, especifically metastatic breast cancer In Vivo PF-06952229 (oral gavage; 30 mg/kg; twice daily; 21 days) combines with Palbociclib 21 days results in an improved inhibition of pSMAD2 in the MCF7 ER + xenograft breast cancer tumor model. This combination also leads to a significant increase in survival relative to PF-06952229 monotherapy . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MCF-7 ER + HER2-xenograft breast cancer tumor model Dosage: 30 mg/kg Administration: Oral gavage; twice daily; 44 days Result: Resulted in an increase in tumor growth inhibition when combined with Palbociclib. IC50& Target:IC50: transforming growth factor-beta receptor 1 (TGFbR1)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
PF-06952229
CAS number：1801333-55-0(DMSO) molecular formula：C23H24ClFN4O3
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1801333-55-0(DMSO) | molecular formula | C23H24ClFN4O3 |
| molecular weight | 458.91 g/mol | Exact mass | 10mM in DMSO |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
